Glenmark Pharmaceuticals Inc. launched Epinephrine Injection USP, 10 mg/10 mL Multiple-Dose Vial on February 27, 2025, which is expected to capture part of the $42.7 million market for this product, while also offering 180 days of CGT exclusivity.